| Medicare Palmetto | Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (58988) | 2025-04-15 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Ultraviolet Light Therapies | 2025-04-14 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Oxaliplatin (Eloxatin) | 2025-04-14 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Sutimlimab-jome (Enjaymo) | 2025-04-14 |
| BCBS Highmark Penn Medicare Advantage | Eptinezumab-jjmr (Vyepti) | 2025-04-14 |
| BCBS Highmark Penn Medicare Advantage | Sutimlimab-jome (Enjaymo) | 2025-04-14 |
| BCBS Highmark Penn Medicare Advantage | Oxaliplatin (Eloxatin) | 2025-04-14 |
| BCBS Highmark NY and West NY | Ultraviolet Light Therapies | 2025-04-14 |
| BCBS Highmark NY and West NY | Sutimlimab-jome (Enjaymo) | 2025-04-14 |
| BCBS Highmark Delaware | Ultraviolet Light Therapies | 2025-04-14 |